Teacher Retirement System of Texas Purchases 915 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Teacher Retirement System of Texas grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,061 shares of the medical equipment provider’s stock after buying an additional 915 shares during the quarter. Teacher Retirement System of Texas’ holdings in Zimmer Biomet were worth $2,742,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of ZBH. Accent Capital Management LLC bought a new position in shares of Zimmer Biomet during the 1st quarter valued at $35,000. Cullen Frost Bankers Inc. lifted its holdings in shares of Zimmer Biomet by 1,452.4% during the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 305 shares during the period. Hilltop National Bank bought a new position in shares of Zimmer Biomet during the 2nd quarter valued at $42,000. Zions Bancorporation National Association UT bought a new position in shares of Zimmer Biomet during the 1st quarter valued at $48,000. Finally, Brooklyn Investment Group lifted its holdings in shares of Zimmer Biomet by 45.9% during the 1st quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock valued at $52,000 after buying an additional 145 shares during the period. 88.89% of the stock is owned by institutional investors.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares in the company, valued at approximately $711,656.95. This represents a 18.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.39% of the company’s stock.

Zimmer Biomet Trading Up 1.2%

Shares of ZBH stock opened at $100.77 on Monday. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $114.72. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The firm has a market capitalization of $19.96 billion, a PE ratio of 24.52, a PEG ratio of 2.29 and a beta of 0.67. The stock has a fifty day simple moving average of $101.45 and a two-hundred day simple moving average of $97.62.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. During the same quarter in the prior year, the business posted $2.01 EPS. Zimmer Biomet’s revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 23.36%.

Analysts Set New Price Targets

Several research firms have recently weighed in on ZBH. Roth Capital reissued a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Rothschild Redb raised Zimmer Biomet to a “strong-buy” rating in a report on Thursday, September 18th. Evercore ISI decreased their target price on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a report on Tuesday, October 7th. UBS Group raised their target price on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a report on Friday, August 8th. Finally, Royal Bank Of Canada set a $111.00 target price on Zimmer Biomet in a report on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $111.94.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.